Clinical Trial Update: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CHOP chemotherapy plus Campath-1H (alemtuzumab) as initial treatment for untreated aggressive T/NK-cell non-Hodgkin lymphoma; trial sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED